Hermetica Superfood Encyclopedia
The Short Answer
Sarcodon scabrosus produces cyathane diterpenes (sarcodonins A and G, neosarcodonins A–C) and p-terphenyl derivatives that exert cytotoxic, anti-inflammatory, antioxidant, and neuritogenic effects through inhibition of cellular proliferation and suppression of inflammatory pathways. The most quantified in vivo finding is topical neosarcodonin C inhibiting TPA-induced mouse ear edema by 87% at a 200 µg dose, while isolated p-terphenyl compounds demonstrate cytotoxicity against SF-268 CNS cancer cells at 93–96% kill rate at 50 µmol/L in vitro.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordSarcodon scabrosus benefits
Bitter Hedgehog Mushroom — botanical close-up
Health Benefits
**Anti-Tumor Activity**
Cyathane diterpenes and p-terphenyl derivatives (compounds 3, 4, 6) eliminate 93–96% of SF-268 CNS cancer cells at 50 µmol/L, and p-terphenyl mixtures (compounds 10/11) halt MCF7 breast cancer cell growth at 100 µmol/L in MTT assays, suggesting multi-target antiproliferative potential.
**Anti-Inflammatory Action**
Sarcodonin A, sarcodonin G, and neosarcodonin C topically suppress 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear edema; neosarcodonin C achieves 87% inhibition at 200 µg, indicating potent modulation of cutaneous inflammatory cascades.
**Free Radical Scavenging and Antioxidant Capacity**
Miscellaneous phenolic compounds 89–91 exhibit DPPH and superoxide radical scavenging with EC50 values of 0.15–0.24 mmol/L, and compound 18 demonstrates a total antioxidant capacity of 225 U, surpassing ascorbic acid (187 U) under equivalent assay conditions.
**Anti-Lipid Peroxidation**
Selected p-terphenyl isolates inhibit lipid peroxidation in membrane model systems, potentially protecting cellular membranes from oxidative damage relevant to neurodegenerative and cardiovascular pathologies.
**Neurite Outgrowth Promotion**
Sarcodonin G and sarcodonin A stimulate neurite outgrowth in rat pheochromocytoma (PC12) cells at 25 mM, a recognized surrogate model for nerve growth factor-like neuroprotective and neurotrophic activity relevant to peripheral and central nerve regeneration.
**Broad-Spectrum Cytotoxicity Across Cancer Cell Lines**
Isolated compounds demonstrate IC50 values of 41.3–51.3 µmol/L against HeLa cervical carcinoma cells, and cytotoxicity has been confirmed across NCI-H460 (lung), KB (nasopharyngeal), and P-388 (murine leukemia) cell lines, indicating chemotype diversity in anticancer mechanisms.
**Cerebroside and Steroid Constituents**
The fruiting bodies yield cerebrosides (compounds 78–82) and steroids (compounds 64–77) that may contribute to membrane integrity modulation and immunomodulatory signaling, though mechanistic studies for these subclasses remain incomplete.
Origin & History
Natural habitat
Sarcodon scabrosus is a terrestrial ectomycorrhizal fungus distributed across temperate forests of Europe, North America, and East Asia, forming symbiotic associations with the roots of conifers such as pine and spruce, as well as select hardwood species. It produces medium-to-large fruiting bodies with a scaly, dark-brown to blackish cap surface and pale, downward-running spines (teeth) on the underside, typically fruiting in late summer through autumn. The mushroom develops a pronounced bitter taste upon maturation, which limits its culinary appeal and has directed research interest almost exclusively toward its pharmaceutical chemistry.
“Sarcodon scabrosus and closely related hedgehog mushrooms (genus Sarcodon) have been noted in broad ethnomycological traditions across East Asia and Europe as potential anti-cancer remedies, though specific documented use of S. scabrosus as a distinct therapeutic agent is sparse compared to more prominent medicinal fungi such as Ganoderma lucidum or Inonotus obliquus. In Chinese traditional medicine contexts, tooth fungi in the Sarcodon genus were occasionally included in folk preparations targeting tumor suppression and immune fortification, though the botanical attribution and preparation protocols are inconsistently recorded in primary historical sources. The mushroom's pronounced and slowly developing bitterness—attributed in part to its bitter diterpene content—likely restricted its culinary use and reinforced its categorization as a medicinal rather than edible species in foraging traditions. Modern scientific interest was catalyzed in the late 20th century by systematic phytochemical surveys of under-studied ectomycorrhizal fungi, leading to the first isolation and characterization of sarcodonin and neosarcodonin compounds from methanol extracts of dried fruiting bodies collected in temperate forest ecosystems.”Traditional Medicine
Scientific Research
The entirety of published evidence for Sarcodon scabrosus consists of in vitro cell-line studies and one ex vivo mouse ear edema model; no randomized controlled trials, observational human studies, or Phase I dose-escalation trials have been published as of the available literature. Cytotoxicity data are derived from standard MTT and NCI-panel assays across KB, P-388, NCI-H460, MCF7, SF-268, and HeLa cell lines, providing reproducible but non-predictive preliminary benchmarks that frequently do not translate to in vivo antitumor efficacy. The anti-inflammatory mouse ear edema study represents the only in vivo bioassay identified, yielding a single quantified endpoint (87% edema inhibition by neosarcodonin C at 200 µg) without pharmacokinetic characterization, dose-response curves, or mechanistic pathway confirmation. The overall evidence base is early-stage preclinical, with research led predominantly by isolation-and-bioassay studies; the absence of ADME data, target identification, in vivo tumor models, and any human data severely limits translational confidence.
Preparation & Dosage
Traditional preparation
**Laboratory Methanol Extract (Research Use Only)**
Dried fruiting bodies extracted with methanol via bioassay-guided fractionation; no standardized extract ratio or commercial specification established.
**Topical Application (Preclinical)**
Neosarcodonin C tested at 200 µg per topical dose in mouse ear edema assay; human-equivalent topical dosing has not been calculated.
**In Vitro Cell Culture Concentrations**
Cyathane diterpenes and p-terphenyl derivatives active at 25–100 µmol/L in cell-based assays; these concentrations are not translatable to oral supplemental doses without pharmacokinetic data.
**Commercial Supplement Forms**
No commercial capsules, powders, tinctures, or standardized extracts of Sarcodon scabrosus are currently documented in peer-reviewed or regulatory literature.
**Traditional Preparation**
Anecdotal records suggest dried whole fruiting bodies in decoction form for traditional anti-cancer applications, but no validated recipe, dose, or preparation protocol is published.
**Standardization**
No marker compound (e.g., % sarcodonin A or neosarcodonin C) has been adopted as a standardization benchmark for any product.
Nutritional Profile
Quantitative nutritional analysis (macronutrients, micronutrients, caloric content) specific to Sarcodon scabrosus fruiting bodies has not been published in available peer-reviewed literature. Like other members of the Basidiomycota, the fruiting body can be expected to contain structural polysaccharides (chitin, beta-glucans), proteins including ergothioneine and free amino acids, and ergosterol (a provitamin D2 precursor) as general fungal constituents, though species-specific concentrations are unquantified. The pharmacologically active phytochemicals include p-terphenyl derivatives (compounds 1–23), cyathane diterpenes (sarcodonins and neosarcodonins; compounds 24–63), steroids (compounds 64–77), cerebrosides (compounds 78–82), and miscellaneous phenolics (compounds 83–100), all isolated from methanol fractions of dried fruiting bodies without quantification in mg/g dry weight. Bioavailability of these compounds via oral ingestion is unknown; the bitter diterpene content and potential instability of isolated compounds under gastrointestinal conditions represent uncharacterized barriers to systemic absorption.
How It Works
Mechanism of Action
The cyathane diterpenes sarcodonin A, sarcodonin G, and neosarcodonins A–C are the primary bioactive scaffold; their strained bicyclic carbon framework is thought to intercalate with or alkylate cellular targets to inhibit tumor cell proliferation, though specific receptor binding data and confirmed molecular targets have not yet been published. Anti-inflammatory activity is mediated through suppression of the arachidonic acid-derived eicosanoid pathway downstream of TPA stimulation, as evidenced by the marked reduction in mouse ear edema; however, the precise enzymatic targets (COX-1/2, LOX, PLA2) have not been definitively identified in published literature. The p-terphenyl derivatives act as potent free radical scavengers, donating hydrogen atoms to neutralize DPPH and superoxide radicals and chelating metal ions to interrupt Fenton-type lipid peroxidation cascades. Neuritogenic activity of sarcodonins in PC12 cells suggests interaction with pathways converging on cytoskeletal remodeling (e.g., MAP kinase or PI3K/Akt signaling analogous to NGF stimulation), though gene expression or phosphoproteomic confirmation is absent from current studies.
Clinical Evidence
No human clinical trials have been conducted with Sarcodon scabrosus extracts or its isolated compounds, and no Investigational New Drug (IND) applications or Phase I studies are documented in available literature. The closest approximation to in vivo evidence is a topical mouse ear edema assay demonstrating 87% anti-inflammatory inhibition by neosarcodonin C at 200 µg, but this model does not establish oral bioavailability, systemic exposure, or human-relevant dosing. Cytotoxic IC50 values in the 41–100 µmol/L range across multiple cancer cell lines are consistent with further mechanistic investigation, but such concentrations have not been contextualized against achievable plasma levels in mammals. Confidence in clinical translation is very low; all observed effects should be considered hypothesis-generating and require rigorous in vivo oncology models, toxicology studies, and eventually controlled human trials before any therapeutic claims can be substantiated.
Safety & Interactions
No formal toxicology studies, maximum tolerated dose assessments, or safety pharmacology evaluations have been published for Sarcodon scabrosus extracts or its isolated compounds in any species, and no adverse events have been reported in the available research literature, which is primarily composed of in vitro bioassay studies. The mushroom is classified as bitter-tasting and potentially inedible due to its diterpene content, and its traditional edibility status is ambiguous; consumption as a food is therefore not recommended without further safety characterization. Drug interactions, contraindications for specific disease states, and effects during pregnancy or lactation are entirely undocumented; given the demonstrated cytotoxic activity of isolated compounds at micromolar concentrations in cancer cell lines, caution is warranted in any clinical or self-supplementation context until appropriate toxicokinetic studies are completed. No maximum safe dose for human use has been established, and current evidence is insufficient to support any supplemental dose recommendation.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Sarcodon scabrosus (Fr.) P. Karst.Bitter Hedgehog MushroomScaly Hedgehog MushroomHydnum scabrosum Fr.Sarcodon imbricatus var. scabrosus
Frequently Asked Questions
What are the main bioactive compounds in Sarcodon scabrosus?
Sarcodon scabrosus contains over 100 characterized compounds grouped into five major classes: p-terphenyl derivatives (compounds 1–23), cyathane diterpenes including sarcodonin A, sarcodonin G, and neosarcodonins A–C (compounds 24–63), steroids (64–77), cerebrosides (78–82), and miscellaneous phenolics (83–100). The cyathane diterpenes and p-terphenyl derivatives are considered the primary pharmacologically active constituents, responsible for observed anti-tumor, anti-inflammatory, antioxidant, and neuritogenic activities in preclinical models.
Does Sarcodon scabrosus have anti-cancer properties?
Preclinical in vitro studies show that isolated p-terphenyl compounds (e.g., compounds 3, 4, 6) kill 93–96% of SF-268 CNS cancer cells at 50 µmol/L, and mixed p-terphenyl fractions halt MCF7 breast cancer cell proliferation at 100 µmol/L, with IC50 values of 41.3–51.3 µmol/L against HeLa cervical cells. However, no animal tumor models or human clinical trials have been conducted, so these findings are hypothesis-generating only and cannot support any claim of anti-cancer efficacy in humans.
Is Sarcodon scabrosus safe to eat or supplement with?
Sarcodon scabrosus is considered bitter-tasting and of ambiguous edibility; no formal human safety studies, toxicology data, or maximum safe dose have been established for either whole mushroom consumption or concentrated extracts. The cytotoxic activity of isolated compounds at micromolar concentrations in cell assays raises unresolved safety questions, and drug interactions and contraindications have not been studied. Until rigorous toxicokinetic and safety pharmacology data are available, consumption or supplementation cannot be recommended.
What is the anti-inflammatory evidence for Sarcodon scabrosus?
The primary anti-inflammatory evidence comes from a topical mouse ear edema assay in which neosarcodonin C inhibited TPA-induced inflammation by 87% at a 200 µg topical dose. Sarcodonin A and sarcodonin G also demonstrated significant inhibition of ear edema in the same ex vivo model; the precise molecular targets (e.g., COX, LOX, or PLA2 enzymes) have not yet been confirmed in mechanistic studies, and no human anti-inflammatory clinical data exist.
Can Sarcodon scabrosus support nerve health or neurite growth?
Sarcodonin G and sarcodonin A at 25 mM have been shown to promote neurite outgrowth in rat PC12 cells, a standard laboratory model used to screen compounds with potential nerve growth factor-like activity relevant to peripheral nerve regeneration and neuroprotection. This finding is structurally analogous to the neurotrophic cyathane diterpenes (erinacines) found in the related medicinal fungus Hericium erinaceus, but Sarcodon scabrosus has not been tested in animal models of neurodegeneration or in any human neurological study, so no therapeutic conclusions can be drawn.
What is the difference between Sarcodon scabrosus extract and whole mushroom powder?
Sarcodon scabrosus extracts concentrate bioactive compounds like cyathane diterpenes and p-terphenyl derivatives, potentially delivering higher levels of antiproliferative and anti-inflammatory compounds compared to whole mushroom powder. Extracts typically undergo solvent-based or hot-water processing to isolate these active metabolites, whereas whole powder retains the full mushroom matrix including fiber and other constituents. For targeted bioactivity research has primarily used isolated extracts at specific concentration ranges (50–100 µmol/L in vitro), making extract forms more directly comparable to clinical study conditions.
Who should avoid Sarcodon scabrosus supplements?
Individuals with known mushroom allergies or sensitivities should avoid Sarcodon scabrosus, as cross-reactivity with other fungi is possible. Those taking immunosuppressive medications should consult a healthcare provider, as the mushroom's immune-modulating and anti-inflammatory properties may interact with such treatments. Pregnant or nursing women should seek medical advice before use, as safety data in these populations is limited.
How does the research evidence for Sarcodon scabrosus compare to other medicinal mushrooms?
Sarcodon scabrosus stands out for its well-characterized cyathane diterpenes and p-terphenyl derivatives, which demonstrate potent in vitro antiproliferative activity (93–96% cell elimination in CNS cancer models), a specificity advantage over broader-spectrum mushrooms like reishi or maitake. However, most evidence for Sarcodon scabrosus remains in vitro and preclinical; human clinical trials are limited compared to more established medicinal mushrooms. The multi-target mechanism against both CNS and breast cancer cell lines in published assays positions it as a unique candidate for further clinical investigation, though translational research is still in early stages.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w bitter-hedgehog-mushroom-sarcodon-scabrosus-fr-p-karst curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
